Granting of a Marketing Authorisation

RNS Number : 8869N

Animalcare Group PLC

04 October 2012

 



Animalcare Group plc

("Animalcare" or the "Group")

Granting of a Marketing Authorisation

Animalcare Group plc (AIM: ANCR) a leading supplier of veterinary medicines, announces that it has been granted a Marketing Authorisation (MA) in a number of key European markets for injectable presentations of the large animal antibiotic marbofloxacin. Animalcare will sell the product in the UK and through its distributors in France and Ireland under the brand name Marbocare.

Marbocare is an addition to Animalcare's range of large animal products and is used primarily in cattle and pigs for the treatment of mastitis and respiratory diseases. In 2011  the UK market for injectable forms of marbofloxacin was worth approximately £2.2m per annum.

Marbocare is another example of successful collaboration between Animalcare and European partners, this being a joint development with a Belgium partner.

The Group has targeted the launch of four new veterinary medicines during the year and following on from the launch of Vitofyllin in September 2012, Marbocare injections will now be the second product launched in the current financial year. 

Stephen Wildridge, CEO of Animalcare Group plc, said:

"We are very pleased that we will shortly be able to bring our second new veterinary medicine to the market in this financial year. Marbocare Injections will be a useful addition to our growing and more modern range of treatments for diseases of livestock which will add impetus to our efforts in this market."

For further information, please contact:

Animalcare Group plc
Stephen Wildridge (Chief Executive Officer)	01904 487 601
N+1 Brewin (Nominated Advisor & Broker)
Aubrey Powell / Richard Lindley	Tel: [phone]
Walbrook PR Ltd	Tel: [phone]
Paul McManus	07980 541 893 or [e-mail]
Helen Westaway	07841 917 679 or [e-mail]

About Animalcare plc - www.animalcaregroup.co.uk

Animalcare Group develops and sells goods and services to veterinary professionals principally for use in companion animals.  It operates directly in the UK and through distribution and development partners in key markets in Western Europe.

Its principal product lines are licensed veterinary medicines and companion animal identification products and services.

 

END

 

 

MSCKMMGGNFMGZZM